RPg Family Wealth Advisory LLC raised its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 88.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 377,090 shares of the company’s stock after purchasing an additional 176,998 shares during the period. RPg Family Wealth Advisory LLC owned 0.12% of Amneal Pharmaceuticals worth $6,527,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Amneal Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock valued at $793,000 after acquiring an additional 4,178 shares in the last quarter. Millennium Management LLC grew its stake in Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after buying an additional 512,842 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at about $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Amneal Pharmaceuticals by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock valued at $2,807,000 after purchasing an additional 16,536 shares in the last quarter. Finally, Creative Planning raised its holdings in shares of Amneal Pharmaceuticals by 61.9% during the 2nd quarter. Creative Planning now owns 23,896 shares of the company’s stock worth $193,000 after buying an additional 9,136 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.
Insider Buying and Selling at Amneal Pharmaceuticals
In other Amneal Pharmaceuticals news, Director John Kiely sold 50,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the sale, the director directly owned 210,252 shares of the company’s stock, valued at $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 over the last three months. 17.30% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Amneal Pharmaceuticals
Amneal Pharmaceuticals Price Performance
Amneal Pharmaceuticals stock opened at $17.54 on Monday. The business’s 50 day simple moving average is $17.68 and its 200 day simple moving average is $14.86. Amneal Pharmaceuticals, Inc. has a 12 month low of $9.32 and a 12 month high of $19.26. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 35.80 and a beta of 1.27. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current year.
Amneal Pharmaceuticals Profile
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Featured Articles
- Five stocks we like better than Amneal Pharmaceuticals
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
